- Home
- ENSG vs EXEL Comparison
ENSG vs EXEL Comparison
Compare ENSG & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ENSG | EXEL |
|---|---|---|
| Founded | 1999 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 11.4B |
| IPO Year | 2007 | 2000 |
Fundamental Metrics
Financial Performance| Metric | ENSG | EXEL |
|---|---|---|
| Price | $183.08 | $44.21 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 21 |
| Target Price | ★ $202.60 | $46.50 |
| AVG Volume (30 Days) | 318.4K | ★ 2.2M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 0.14% | N/A |
| EPS Growth | 14.06 | ★ 57.95 |
| EPS | 1.67 | ★ 2.78 |
| Revenue | ★ $5,057,841,000.00 | $452,477,000.00 |
| Revenue This Year | $17.07 | $13.61 |
| Revenue Next Year | $9.49 | $13.13 |
| P/E Ratio | $110.17 | ★ $15.73 |
| Revenue Growth | ★ 18.72 | N/A |
| 52 Week Low | $129.91 | $33.76 |
| 52 Week High | $218.00 | $48.74 |
Technical Indicators
Market Signals| Indicator | ENSG | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 30.05 | 49.35 |
| Support Level | $168.63 | $43.53 |
| Resistance Level | $187.63 | $44.32 |
| Average True Range (ATR) | 5.84 | 1.33 |
| MACD | -0.92 | -0.22 |
| Stochastic Oscillator | 11.80 | 16.12 |
Price Performance
Historical ComparisonAbout ENSG The Ensign Group Inc.
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.